Supercomputer simulations have shown that clusters of a protein linked to cancer warp cell membranes, according to scientists at The University of Texas Health Science Center at Houston (UTHealth) Medical School. This research on these protein clusters, or aggregates as scientists call them, could help guide design of new anticancer drugs.
Current drug-delivery systems used to administer chemotherapy to cancer patients typically release a constant dose of the drug over time - but a new study challenges this "slow and steady" approach and offers a novel way to locally deliver the drugs "on demand," as reported in the Proceedings of the National Academy of Sciences (PNAS).
PeptiMed announced today that under a Material Transfer Agreement it will collaborate with the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL), located at the Frederick National Laboratory of Cancer Research in Frederick, MD.
Pacemaker research from the Universities of Bath and Bristol could revolutionise the lives of over 750,000 people who live with heart failure in the UK.
Celsion Corporation (Celsion), an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of two clinical trials with its nanotechnology-based loteprednol etabonate MPP (LE-MPP) program, KPI-121.
CEA-Leti and Akrivis Technologies, LLC announced their collaboration to develop an extremely adaptable, efficient and highly targeted drug delivery platform for chemotherapy and other treatments that require a high concentration of powerful drugs to be delivered precisely to targeted cells.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology.
Several prominent speakers from across the globe that are part of Nanotek-2014 include Claudio Nicolini, Nanoworld Institute, Italy; Haruo Sugi, Teikyo University School of Medicine, Japan; Jim Klostergaard, MD Anderson Cancer Center, The University of Texas, USA; Israel Felner, The Hebrew University, Israel; Jean-Paul (Moshe) Lellouche, Bar-Ilan University, Israel; John F. Donegan, Trinity College Dublin, Ireland; Ashok K. Vaseashta, International Clean Water Institute, USA,; Kimihisa Yamamoto, Tokyo Institute of Technology, Japan; Serhii Shafraniuk, Northwestern University, USA; Mark Kester, NanoSTAR Institute of the University of Virginia, USA; Bjarne Bogen, University of Oslo and Oslo University Hospital, Norway; and Moinuddin Sarker, Natural State Research, Inc., USA.
Researchers from Tel Aviv University and partner institutions develop device that spots lung cancer to stop it in its tracks
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.